10x Genomics (TXG) Stock Forecast & Price Target

Compare

1,217 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TXG Analyst Ratings

Moderate Buy

3 Buy

8 Hold

0 Sell

Based on 11 analysts giving stock ratings to

10x

Genomics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TXG Stock 12 Month Forecast

Average Price Target

$17.60

▲(9.66% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $17.60 with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a 9.66% change from the last price of $16.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","11":"$11","15":"$15","19":"$19","23":"$23"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,11,15,19,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.08,18.38153846153846,18.68307692307692,18.984615384615385,19.286153846153844,19.587692307692308,19.889230769230767,20.19076923076923,20.49230769230769,20.793846153846154,21.095384615384614,21.396923076923077,21.698461538461537,{"y":22,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.08,18.04307692307692,18.006153846153843,17.96923076923077,17.932307692307692,17.895384615384614,17.858461538461537,17.821538461538463,17.784615384615385,17.747692307692308,17.71076923076923,17.673846153846156,17.63692307692308,{"y":17.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.08,17.766153846153845,17.45230769230769,17.138461538461538,16.824615384615385,16.51076923076923,16.196923076923078,15.883076923076922,15.569230769230769,15.255384615384614,14.94153846153846,14.627692307692307,14.313846153846153,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.47,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.36,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.39,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.08,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$22.00

Average Price Target$17.60

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kyle Mikson CFA

Canaccord Genuity

$19→$20

Buy

24.61%

Upside

Reiterated

12/22/25

10x Genomics price target raised to $20 from $19 at Canaccord10x Genomics price target raised to $20 from $19 at Canaccord

Michael Ryskin

Bank of America Securities

$15→$18

Hold

12.15%

Upside

Reiterated

12/15/25

Bank of America Securities Reaffirms Their Hold Rating on 10x Genomics (TXG)

Luke Sergott

Barclays

$17→$22

Buy

37.07%

Upside

Reiterated

12/15/25

Barclays Keeps Their Buy Rating on 10x Genomics (TXG)

Patrick B Donnelly

Citi

$18

Hold

12.15%

Upside

Downgraded

12/11/25

Citi downgrades 10x Genomics (TXG) to a Hold

Kallum Titchmarsh

Morgan Stanley

$17→$20

Hold

24.61%

Upside

Downgraded

12/01/25

10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley

David Westenberg

Piper Sandler

$15→$19

Hold

18.38%

Upside

Reiterated

11/11/25

10x Genomics price target raised to $19 from $15 at Piper Sandler10x Genomics price target raised to $19 from $15 at Piper Sandler

Daniel Brennan

TD Cowen

$14→$15

Hold

-6.54%

Downside

Reiterated

11/07/25

10x Genomics: Hold Rating Amid Resilience and Challenges in U.S. Academic and Government Sectors

Dan Leonard

UBS

$13→$14

Hold

-12.77%

Downside

Reiterated

11/07/25

10x Genomics price target raised to $14 from $13 at UBS10x Genomics price target raised to $14 from $13 at UBS

Daniel Arias

Stifel Nicolaus

$15

Buy

-6.54%

Downside

Reiterated

11/07/25

Stifel Nicolaus Sticks to Their Buy Rating for 10x Genomics (TXG)

Matt Larew

William Blair

Hold

―

Assigned

11/07/25

10x Genomics: Balancing Growth Potential with Macroeconomic Challenges - Hold Rating Maintained

Casey Woodring

J.P. Morgan

$15

Hold

-6.54%

Downside

Reiterated

11/07/25

10x Genomics price target raised to $15 from $13 at JPMorgan10x Genomics price target raised to $15 from $13 at JPMorgan

Puneet Souda

Leerink Partners

$15→$16

Hold

-0.31%

Downside

Reiterated

08/11/25

Leerink Partners Remains a Hold on 10x Genomics (TXG)

Justin Bowers

Deutsche Bank

$10→$14

Hold

-12.77%

Downside

Reiterated

08/08/25

10x Genomics price target raised to $14 from $10 at Deutsche Bank10x Genomics price target raised to $14 from $10 at Deutsche Bank

Subbu Nambi

Guggenheim

Hold

―

Reiterated

02/23/25

We expect TXG to share more on what these new products will mean for the research community and their competitive positioning at AGBT, especially given other updates from the likes of BRKR and ILMN heading into the conference. *** We will be attending AGBT in person. If you are there and want to meet, let us know. Also, please email us if you want to schedule a time to chat after.

Tycho Peterson

Jefferies

$19

Buy

18.38%

Upside

Reiterated

02/12/25

Positive Outlook for 10x Genomics Amid Strong Financials and Growth Prospects

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kyle Mikson CFA

Canaccord Genuity

$19→$20

Buy

24.61%

Upside

Reiterated

12/22/25

10x Genomics price target raised to $20 from $19 at Canaccord10x Genomics price target raised to $20 from $19 at Canaccord

Michael Ryskin

Bank of America Securities

$15→$18

Hold

12.15%

Upside

Reiterated

12/15/25

Bank of America Securities Reaffirms Their Hold Rating on 10x Genomics (TXG)

Luke Sergott

Barclays

$17→$22

Buy

37.07%

Upside

Reiterated

12/15/25

Barclays Keeps Their Buy Rating on 10x Genomics (TXG)

Patrick B Donnelly

Citi

$18

Hold

12.15%

Upside

Downgraded

12/11/25

Citi downgrades 10x Genomics (TXG) to a Hold

Kallum Titchmarsh

Morgan Stanley

$17→$20

Hold

24.61%

Upside

Downgraded

12/01/25

10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley10x Genomics assumed at Equal Weight from Overweight at Morgan Stanley

David Westenberg

Piper Sandler

$15→$19

Hold

18.38%

Upside

Reiterated

11/11/25

10x Genomics price target raised to $19 from $15 at Piper Sandler10x Genomics price target raised to $19 from $15 at Piper Sandler

Daniel Brennan

TD Cowen

$14→$15

Hold

-6.54%

Downside

Reiterated

11/07/25

10x Genomics: Hold Rating Amid Resilience and Challenges in U.S. Academic and Government Sectors

Dan Leonard

UBS

$13→$14

Hold

-12.77%

Downside

Reiterated

11/07/25

10x Genomics price target raised to $14 from $13 at UBS10x Genomics price target raised to $14 from $13 at UBS

Daniel Arias

Stifel Nicolaus

$15

Buy

-6.54%

Downside

Reiterated

11/07/25

Stifel Nicolaus Sticks to Their Buy Rating for 10x Genomics (TXG)

Matt Larew

William Blair

Hold

―

Assigned

11/07/25

10x Genomics: Balancing Growth Potential with Macroeconomic Challenges - Hold Rating Maintained

Casey Woodring

J.P. Morgan

$15

Hold

-6.54%

Downside

Reiterated

11/07/25

10x Genomics price target raised to $15 from $13 at JPMorgan10x Genomics price target raised to $15 from $13 at JPMorgan

Puneet Souda

Leerink Partners

$15→$16

Hold

-0.31%

Downside

Reiterated

08/11/25

Leerink Partners Remains a Hold on 10x Genomics (TXG)

Justin Bowers

Deutsche Bank

$10→$14

Hold

-12.77%

Downside

Reiterated

08/08/25

10x Genomics price target raised to $14 from $10 at Deutsche Bank10x Genomics price target raised to $14 from $10 at Deutsche Bank

Subbu Nambi

Guggenheim

Hold

―

Reiterated

02/23/25

Tycho Peterson

Jefferies

$19

Buy

18.38%

Upside

Reiterated

02/12/25

Positive Outlook for 10x Genomics Amid Strong Financials and Growth Prospects

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering 10x Genomics

1 Month

xxx

Success Rate

14/26 ratings generated profit

Average Return

-0.35%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of -0.35% per trade.

3 Months

xxx

Success Rate

9/21 ratings generated profit

Average Return

-2.84%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -2.84% per trade.

1 Year

Daniel AriasStifel Nicolaus

Success Rate

10/21 ratings generated profit

Average Return

-7.84%

reiterated a buy rating 2 months ago

Copying Daniel Arias's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of -7.84% per trade.

2 Years

xxx

Success Rate

12/26 ratings generated profit

Average Return

-3.28%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 46.15% of your transactions generating a profit, with an average return of -3.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TXG Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TXG has received 8 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. TXG average Analyst price target in the past 3 months is 17.60.

Each month's total comprises the sum of three months' worth of ratings.

TXG Financial Forecast

TXG Earnings Forecast

Next quarter’s earnings estimate for TXG is -$0.22 with a range of -$0.33 to -$0.13. The previous quarter’s EPS was -$0.22. TXG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year TXG has Performed in-line its overall industry.

TXG Sales Forecast

Next quarter’s sales forecast for TXG is $156.00M with a range of $154.10M to $157.20M. The previous quarter’s sales results were $149.00M. TXG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year TXG has Performed in-line its overall industry.

TXG Stock Forecast FAQ

What is TXG’s average 12-month price target, according to analysts?

Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is 17.60.

What is TXG’s upside potential, based on the analysts’ average price target?

10x Genomics Inc has 9.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TXG a Buy, Sell or Hold?

10x Genomics Inc has a consensus rating of Moderate Buy which is based on 3 buy ratings, 8 hold ratings and 0 sell ratings.

What is 10x Genomics Inc’s price target?

The average price target for 10x Genomics Inc is 17.60. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $14.00. The average price target represents 9.66% Increase from the current price of $16.05.

What do analysts say about 10x Genomics Inc?

10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of TXG?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

10x Genomics (TXG) Stock Forecast & Price Target

TXG Analyst Ratings

TXG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering 10x Genomics

TXG Analyst Recommendation Trends

TXG Financial Forecast

TXG Earnings Forecast

TXG Sales Forecast

TXG Stock Forecast FAQ

Detailed List of Analyst Forecasts